06.26.18 Reno, NV Cyrcadia Health Announces New Medical Advisor, Kevin Buckman, M.D.

Dr. Buckman has over 35 years of Emergency Medicine Experience and is currently a Physician with Team Health in Lodi, CA. He has served as Medical Director or Associate Medical Director in hospitals and institutions for over 20 years and has over 40 years of clinical experience. He has served as Medical Director in the Emergency Department and as a member of the Executive Committee for six years at St. Dominic’s Hospital in Manteca, California. He also served as Director of the Emergency Department at Navy Lemoore Hospital in California. Dr. Buckman is the author of many books, including Find & Stop Breast Cancer, The Metabolic Origin of Cancer. He was a Fellow in the American Association of Integrated Medicine, and is a Board Certified Medical Review Officer. He has been certified with the National Registry of Certified Medical Examiners since 2014. His other specialties include: Internal Medicine, Forensic Medicine, Medical Acupuncture. He has presented research, published articles and books in the field of medicine, and given lectures at numerous hospitals and at International Medical Conferences. He has received Post Graduate Training at Stanford University School of Business and attended seminars with the Securities Exchange Institute. He has numerous Medical Publications, including topics on breast cancer, oncology, and other topics. He was the first US Physician to be accepted into the European Group for Breast Cancer Screening after his research in this field was accepted for publication and presentation at their international conference in Cyprus. During the last 30 years he has worked to advance a number of medical technologies with a focus on Non-Harmful early detection of disease,...

Reno, NV June 12, 2018, Cyrcadia, Inc. New Member of Board of Directors

Cyrcadia, Inc. is pleased to announce the addition of Ed Wertzberger to the Board of Directors as we continue to focus on implementation of our aggressive growth strategy and Go-To-Market plan. Jim Holmes, Chairman of the Board, says, “We are pleased to have an executive join our Board who possesses extensive leadership and global experience. We are confident Ed’s 35 years of leadership, financial management and operational consulting and governance experience will bring a fresh perspective and insights as we implement our product plans.” Matt Benardis, CEO, added “We have already seen impact from Ed’s involvement as we review and negotiate company contracts and develop corporate policies and governance”. Ed’s leadership background includes management experience in global leadership roles with the “Big Four” accounting firms, consulting for Fortune 500 companies, led hospital transformations, and is the co-founder of a boutique management consulting firm. In addition, Ed’s experience includes over 20 years as a partner with Arthur Andersen and Deloitte, Big Four firms. He has led global strategy planning and implementation initiatives, business transformation and customer loyalty programs. He has been a member of numerous leadership and governance teams to align operations and implementation teams. He has served on numerous not-for-profit organization Board’s, including as President for several. Ed’s educational background includes a Bachelor of Business Administration – Accounting from the University of Iowa and he obtained his CPA in 1976. Next steps: Announce new product and new chief medical...

Reno, NV May 29, 2018, Cyrcadia Health “B” Warrant Acceleration Option

Based on 2018 Go-To-Market plans, investment infusion is paramount in keeping on track and maintaining our accelerated pace. Our stakeholders have been essential in supporting our march to bring the most advanced Breast Health product to market. For those stakeholders holding “B” warrants, the warrants will expire December 31, 2018, meaning conversion to shares in the company will no longer be an option, losing all value. Accordingly, we are offering a “B” Warrant acceleration option effective now until June 30, 2018 allowing our stakeholders to continue to be part of and support the next phase of company operations: “B” Warrant Conversion price: $0.50 per warrant. “E” Warrant Addition: for each “B” Warrant converted to shares on or before June 30, 2018, Cyrcadia, Inc. will offer one (1) “E” warrant for each “B” Warrant converted, with an exercise date of December 31, 2019 at $1.00 per warrant. “This acceleration option allows our warrant holders to extend their expiration date while supporting our plans with the investment infusion at this time”, says Jim Holmes, CFO. “Warrant holders should note that new investors are investing at $1.00 per share and this acceleration option extends the time to participate in the increased value of the company as we achieve our market and sales milestones”, adds Holmes Direct inquiries to Jim Holmes at 775-852-3222 or email to...

Reno, NV May 21, 2018, Key Partnerships for Cyrcadia Health

Three key partner relationships are in place to bring “Best of Breed” subject matter experts into the Cyrcadia Health, Go-To-Market sales launch plan: Consumer Marketing: Dupuis Marketing, Chicago: branding, packaging, social media advertising, and user experience design. “We develop and create business opportunities that establish new meaning for people–digging for deeper truths beyond commonly leveraged insights, evolving brand relevance and creating breakthrough products and services. We translate our clients’ business challenges into sustainable, responsible growth opportunities.” Clinical Marketing: Life Sciences Strategy Group, San Jose: product visualization, product and market strategy. “Our approach employs best practices to align strategy with portfolio management and product development and commercialization processes. This integrated solution results in alignment of near, short and long–term planning cycles and development of strong and actionable marketing/brand, portfolio, new product, licensing and managed market strategies.” Nerdy Dragon, Boise: IT infrastructure and web site management. “Nerdy Dragon is a connector and collaborative agency focused on digital asset design, production, and management. We deliver for clients – consistently, reliably, with world class quality and super-reasonable turnaround. We have designed and developed hundreds of web and app experiences since 2009. We are a team of over 300, located on 5 continents, working tirelessly to execute on digital projects – making, doing, connecting, and thriving. We have team members located in the US, South America, Australia, Asia, and Africa.” “Principals of these companies have been involved with Cyrcadia Health for a number of years and have a deep understanding of our value proposition to bring significant value to our Go-To-Market launch,” says Matt Benardis, CEO. “Their depth of experience in our markets means...

May 14, 2018, Reno, NV. Artificial Intelligence Advancements

New discoveries have been achieved with our artificial intelligence (AI) algorithms. Recalling the foundational basis for the Cyrcadia Health intellectual property and patent filings is five algorithms that analyze tissue temperature and circadian body rhythm disruptions over a time period (dynamic) to identify tissue abnormalities. “Recently, our AI software scientists have made new discoveries that will bring additional value to our users who want to understand their health condition”, says Matt Benardis, CEO. Advanced data analysis and formula modification has achieved three goals: The science of ability to locate a tissue liesion abnormality location has now been verified. This means a doctor will know where to start more advanced therapies. Location is significant, as this will allow the physician to focus on a specific area for further investigation. With additional data from our clinical studies, we can advance our tissue knowledge without having to re-engineer our device and sensors. A new Wellness score can be computed based on metabolic patterns that can be used to begin tracking behaviors on the basis of clinical trial data. Wear time can now be as little as two hours. Analysis of datasets has detected the same statistical probability in a two hour dataset as in an 8 hour dataset. This means the Circadian disruption is perpetuated throughout the circadian cycle, leaving a detectable “signature”. This signature means the metabolic behavior can be identified for continued observation. Our four clinical trials continue to show the same successful outcomes through our analysis of this thermo-circadian disruption caused by abnormal breast tissue (via morphological and endocrine factors) and the resulting dynamic temperature patterns. In addition, we...
May 4, 2018, Reno, NV. Expanded Go-To-Market Team

May 4, 2018, Reno, NV. Expanded Go-To-Market Team

Cyrcadia, Inc. is pleased to announce the addition of Marly Heidkamp, Chief Operating Officer, R.N., MSEd to the executive team to focus on execution of the Go-to- Market plan. Jim Holmes, CFO, say, “We are pleased to have an operations executive join our team who possesses medical product management experience as well. We are confident her leadership will bring added perspective to a product targeted for the female population.” Matt Benardis, CEO, added “We have already seen results from her leadership of the recent kick-off meeting with the comprehensive Go-To- Market team and her engagement of each department regarding oversight, organization and accountability.” Please see the attached Team photo from a very successful kick-off. Marly brings over 30 years of healthcare and corporate operations depth, as well as consulting and management experience to our team. Her career also includes experience as a pediatrics and specialty care nursery nurse. Consulting lessons learned include experience in Healthcare, Big Four, Fortune 500 professional services and software environments, plus co-founding and managing a boutique management consulting business for over 10 years. Ms. Heidkamp’s operations experience in healthcare and software environments include leadership roles in electronic health records software, healthcare consulting, hospital-wide training and education, vendor credentialing program and software for hospitals, hospital business transformation, strategic planning and execution and customer loyalty programs. Her educational background includes Masters of Science in Adult Learning, with emphasis in Organizational Development, Instructional Design and Change Management (Northern Illinois University in DeKalb, IL), Bachelor of Science in Nursing (Benedictine University, Lisle, IL) and Certificate in Leading People, Leading Organizations (USC Marshall School of Business). Please join us in...

April 30, 2018, Reno, NV. Clinical Trial Resumption Update

As Cyrcadia prepares to move to clinical markets, Matt Benardis, CEO; Jim Holmes, CFO; along with our Clinical Research associate (CRA) met with clinical trial investigators and administration at El Camino Hospital, in San Mateo, CA, to discuss previous participant follow-up and trial resumption with our modified clinical product and associated study protocol. Do note trial details are not revealed in advance nor can Cyrcadia, Inc., the study Sponsor, have any impact on the procedures in order to maintain FDA trial integrity. However, they did ascertain a number of positive aspects with El Camino trial manager Initial trial participant follow-up continues to contribute to the Artificial Intelligence analytics improvement and population of the database. Trial managers confirmed their agreement and enthusiasm for protocol revisions regarding the reduction of wear time for trail participants to 2 hours, potentially accelerating participant subscription. Trial managers were very positive and affirmed their ongoing interest in the resumption of the study and its completion providing study outcome data for FDA disclosure. It is important to understand one of our issues was women recently diagnosed with breast cancer were reluctant to be committed to an up to 24-hour wear time. All agreed that our revised 2-hour wear time protocol would potentially increase participation and accelerate trial completion. It is notable that our artificial intelligence algorithm research has developed verifiable evidence to substantiate a 2-hour wear time with equivalent accuracy results as compared to the historical 24-hour wear time. Next steps Updated production schedule from Jabil Electronics and Cyrcadia Asia to provide product revisions related to shelf life and improved ease of use, as well as...

Cyrcadia, Inc. – 2017 Year End and 2018 Look Forward Newsletter

February 27, 2018 Cyrcadia, Inc. (“CI”) extends its thanks and appreciation in your interest and support of our endeavors. We are taking this opportunity to provide an update, as well as apprise you of upcoming expectations. License and Cooperation Agreement with Cyrcadia Asia (“CA”) – Status Earlier in 2017 CI entered into an Agreement with CA, whereby CA assumed the responsibility and funding of the design, development and delivery of a scalable, commercializable iTBra™ system including upgraded hardware and the full suite of application software as well as automation of our proprietary Artificial Intelligence Analytics. The estimated cost of development with Jabil and Mobile Now is approximately $1.2 to $1.5 million US. As such, the agreement calls for CA to provide timely reporting and status of product development including timelines, milestones and dates of completion and delivery of product (market readiness, product volume availability and delivery terms and schedules). Many strides have been made in the evolution of the relationship as CA has established its operations, initial staffing and funding. Both CI and CA are in a mode of cooperation, as called for by the Agreement and, presently, both entities are to hold routine meetings where comprehensive updating and reporting will be delivered to CI, enabling implementation of our business, operations and marketing plans. We will be reporting the outcomes of that meeting to move forward on our ability to commercialize the iTBra™ system this year. Given the above, we would like to update on the internal operations that will allow for CI to “hit the ground running” upon product delivery. Status of Product Development and Manufacturing Under CA’s...

Cyrcadia, Inc. Wins Prestigious Cannes Lions Awards

Cyrcadia, Inc. (CI) announced it has won two prestigious awards at the Cannes Lions International Festival of Creativity, a global event for the creative communications, marketing and advertising world. Held in Cannes, France and attended by over 10,000 delegates, Lion awards are considered the most coveted in the industry. The first award was a Bronze Lion in the category of Innovation, which honors ground-breaking technology and problem-solving. It specifically looks at how technology, data and ideas, when working in unison, can revolutionize lives. Cyrcadia shared the Bronze award with industry giants such as Google, Shell and Apple. The second award was a Silver Glass Lion award, recognizing ideas that could change the world and positively impact gender inequality or injustice. Cyrcadia’s ability to deliver early breast cancer health monitoring to the mass populations of women who have little or no access to quality health care was key to Cyrcadia’s award achievement. Cyrcadia is developing and marketing a device and software that monitors for biometric changes that correlate to breast cancer . Known as the iTBra, the device is based on wearable sensor patches that are placed under a woman’s own garments and worn for two hours. The sensor data results processed through Cyrcadia’s artificial intelligence (AI) lab can be automatically communicated to the patient, her physician and insurance company. Based on Cyrcadia’s monitoring device, a patient will be recommended for further investigation by a physician. The company’s technology has obtained U.S. FDA 510(k) Class II clearance. While the technology is based on historic data from a trial of 200 patients, recent validation trials on 46 patients have confirmed prior...

Lifeline announces transfer of breast cancer detection technology to subsidiary

Reno-based Lifeline Biotechnologies, Inc. (OTC PINK: LLBO) recently transferred breast cancer detection technology to Cyrcadia, Inc. in exchange for 4,670,000 shares of Cyrcadia, Inc. common stock and a $110,000 cash and $220,000 promissory note. The additional 4,670,000 shares added to Lifeline’s original 8,000,000 shares totals 12,670,000 shares. Lifeline’s ownership is increased to over 45 percent of Cyrcadia, Inc., making Lifeline Cyrcadia, Inc.’s largest single shareholder. The technology transfer enabled Cyrcadia, Inc. to license Cyrcadia Asia Limited for the marketing of Cyrcadia, Inc. products throughout the Asian markets. Rob Royea, Cyrcadia, Inc.’s former CEO, is moving to Hong Kong to manage the Asian opportunity, representing a population of 1.8 billion people. Cyrcadia, Inc. received the following compensation for the license to Cyrcadia Asia Limited: An $830,000 Cyrcadia, Inc. equity investment at $1.00 per share with an equal $1.00 warrant; a $1,050,000 promissory note; Cyrcadia Asia, Limited assumed approximately $3,000,000 in product development costs for the Bluetooth and added sensor costs. Cyrcadia, Inc. received an equity interest in Cyrcadia Asia, Limited. Additionally, Cyrcadia Asia Limited assumed approximately $500,000 of Cyracdia, Inc.’s annual general and administrative expenses. Cyrcadia Asia Limited will license Cyrcadia, Inc. for the developed Bluetooth and additional sensors products once development is completed. The transaction is valued at approximately $5 million. The Bluetooth capabilities will enable patient data to be transmitted directly, over the Internet, to the testing physician, and/or the data interpretation center. The added sensors will enable the systems to exactly locate the tissue abnormality or cancer within the breast tissue. By locating the abnormality, the physician performing the biopsy will know exactly where the probe should be inserted into the tissue. Cyrcadia, Inc., a Nevada corporation, founded by...